AbbVie says EU approves Rinvoq for children with polyarticular juvenile idiopathic arthritis
Bitget2026/09/22 06:01- European Commission cleared AbbVie’s Rinvoq for active polyarticular juvenile idiopathic arthritis in patients aged 2 and older.
- Use targets children who failed or cannot tolerate at least one DMARD; dosing includes 15 mg tablets or weight-based oral solution.
- Decision relied on the open-label Phase 1 SELECT-YOUTH pediatric study, supported by adult rheumatoid arthritis data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
